@misc{hebert_m.f._what_1990,
	title = {What is the {Clinical} {Role} of {Aerosolized} {Ribavirin}?},
	url = {http://aop.sagepub.com/content/by/year},
	abstract = {Aerosolized ribavirin is the first approved agent for the treatment of respiratory syncytial virus (RSV) infection. However, the clinical use of ribavirin is controversial. Although ribavirin-treated patients appear to be subjectively improved, the benefit in terms of decreased morbidity and mortality is not well established. Furthermore, the drug has been found to be teratogenic, carcinogenic, and mutagenic, depending upon the scientific model. Because of its unique mode of administration, environmental exposure of healthcare personnel and other patients may occur. Although administration in mechanically ventilated patients decreases the amount of ribavirin liberated into the atmosphere, the drug crystallizes in the endotracheal tube, occasionally resulting in reduced ventilation. The lack of data documenting efficacy and the above environmental concerns result in difficult decisions for hospitals. Further studies are necessary to clarify the value and safety of ribavirin in the treatment of RSV infection. Copyright © 1990, © 1990 SAGE Publications.},
	journal = {Annals of Pharmacotherapy},
	author = {{Hebert M.F.} and {Guglielmo B.J.}},
	year = {1990},
	keywords = {*aerosol, *ribavirin, *ribavirin/ad [Drug Administration], *ribavirin/ae [Adverse Drug Reaction], *ribavirin/cm [Drug Comparison], *ribavirin/pd [Pharmacology], *ribavirin/pe [Pharmacoeconomics], *ribavirin/po [Oral Drug Administration], Pharmacokinetics, arterial oxygen tension, article, artificial ventilation, atmosphere, clinical article, clinical trial, crystallization, disease severity, drug cost, drug efficacy, drug therapy, dyspnea/si [Side Effect], endotracheal tube, environmental exposure, health care personnel, hospital, hospital admission, hospitalization, human, infant, lung function test, morbidity, mortality, placebo, priority journal, respiratory syncytial virus infection, safety, teratogenesis, treatment duration, ventilated patient, wheezing/si [Side Effect]}
}

{"_id":"AgR6nFHnv8RRvktvt","bibbaseid":"hebertmf-guglielmobj-whatistheclinicalroleofaerosolizedribavirin-1990","downloads":0,"creationDate":"2017-05-12T20:20:57.441Z","title":"What is the Clinical Role of Aerosolized Ribavirin?","author_short":["Hebert M.F.","Guglielmo B.J."],"year":1990,"bibtype":"misc","biburl":"http://bibbase.org/zotero/gxu917","bibdata":{"bibtype":"misc","type":"misc","title":"What is the Clinical Role of Aerosolized Ribavirin?","url":"http://aop.sagepub.com/content/by/year","abstract":"Aerosolized ribavirin is the first approved agent for the treatment of respiratory syncytial virus (RSV) infection. However, the clinical use of ribavirin is controversial. Although ribavirin-treated patients appear to be subjectively improved, the benefit in terms of decreased morbidity and mortality is not well established. Furthermore, the drug has been found to be teratogenic, carcinogenic, and mutagenic, depending upon the scientific model. Because of its unique mode of administration, environmental exposure of healthcare personnel and other patients may occur. Although administration in mechanically ventilated patients decreases the amount of ribavirin liberated into the atmosphere, the drug crystallizes in the endotracheal tube, occasionally resulting in reduced ventilation. The lack of data documenting efficacy and the above environmental concerns result in difficult decisions for hospitals. Further studies are necessary to clarify the value and safety of ribavirin in the treatment of RSV infection. Copyright © 1990, © 1990 SAGE Publications.","journal":"Annals of Pharmacotherapy","author":[{"firstnames":[],"propositions":[],"lastnames":["Hebert M.F."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Guglielmo B.J."],"suffixes":[]}],"year":"1990","keywords":"*aerosol, *ribavirin, *ribavirin/ad [Drug Administration], *ribavirin/ae [Adverse Drug Reaction], *ribavirin/cm [Drug Comparison], *ribavirin/pd [Pharmacology], *ribavirin/pe [Pharmacoeconomics], *ribavirin/po [Oral Drug Administration], Pharmacokinetics, arterial oxygen tension, article, artificial ventilation, atmosphere, clinical article, clinical trial, crystallization, disease severity, drug cost, drug efficacy, drug therapy, dyspnea/si [Side Effect], endotracheal tube, environmental exposure, health care personnel, hospital, hospital admission, hospitalization, human, infant, lung function test, morbidity, mortality, placebo, priority journal, respiratory syncytial virus infection, safety, teratogenesis, treatment duration, ventilated patient, wheezing/si [Side Effect]","bibtex":"@misc{hebert_m.f._what_1990,\n\ttitle = {What is the {Clinical} {Role} of {Aerosolized} {Ribavirin}?},\n\turl = {http://aop.sagepub.com/content/by/year},\n\tabstract = {Aerosolized ribavirin is the first approved agent for the treatment of respiratory syncytial virus (RSV) infection. However, the clinical use of ribavirin is controversial. Although ribavirin-treated patients appear to be subjectively improved, the benefit in terms of decreased morbidity and mortality is not well established. Furthermore, the drug has been found to be teratogenic, carcinogenic, and mutagenic, depending upon the scientific model. Because of its unique mode of administration, environmental exposure of healthcare personnel and other patients may occur. Although administration in mechanically ventilated patients decreases the amount of ribavirin liberated into the atmosphere, the drug crystallizes in the endotracheal tube, occasionally resulting in reduced ventilation. The lack of data documenting efficacy and the above environmental concerns result in difficult decisions for hospitals. Further studies are necessary to clarify the value and safety of ribavirin in the treatment of RSV infection. Copyright © 1990, © 1990 SAGE Publications.},\n\tjournal = {Annals of Pharmacotherapy},\n\tauthor = {{Hebert M.F.} and {Guglielmo B.J.}},\n\tyear = {1990},\n\tkeywords = {*aerosol, *ribavirin, *ribavirin/ad [Drug Administration], *ribavirin/ae [Adverse Drug Reaction], *ribavirin/cm [Drug Comparison], *ribavirin/pd [Pharmacology], *ribavirin/pe [Pharmacoeconomics], *ribavirin/po [Oral Drug Administration], Pharmacokinetics, arterial oxygen tension, article, artificial ventilation, atmosphere, clinical article, clinical trial, crystallization, disease severity, drug cost, drug efficacy, drug therapy, dyspnea/si [Side Effect], endotracheal tube, environmental exposure, health care personnel, hospital, hospital admission, hospitalization, human, infant, lung function test, morbidity, mortality, placebo, priority journal, respiratory syncytial virus infection, safety, teratogenesis, treatment duration, ventilated patient, wheezing/si [Side Effect]}\n}\n\n","author_short":["Hebert M.F.","Guglielmo B.J."],"key":"hebert_m.f._what_1990","id":"hebert_m.f._what_1990","bibbaseid":"hebertmf-guglielmobj-whatistheclinicalroleofaerosolizedribavirin-1990","role":"author","urls":{"Paper":"http://aop.sagepub.com/content/by/year"},"keyword":["*aerosol","*ribavirin","*ribavirin/ad [Drug Administration]","*ribavirin/ae [Adverse Drug Reaction]","*ribavirin/cm [Drug Comparison]","*ribavirin/pd [Pharmacology]","*ribavirin/pe [Pharmacoeconomics]","*ribavirin/po [Oral Drug Administration]","Pharmacokinetics","arterial oxygen tension","article","artificial ventilation","atmosphere","clinical article","clinical trial","crystallization","disease severity","drug cost","drug efficacy","drug therapy","dyspnea/si [Side Effect]","endotracheal tube","environmental exposure","health care personnel","hospital","hospital admission","hospitalization","human","infant","lung function test","morbidity","mortality","placebo","priority journal","respiratory syncytial virus infection","safety","teratogenesis","treatment duration","ventilated patient","wheezing/si [Side Effect]"],"downloads":0,"html":""},"search_terms":["clinical","role","aerosolized","ribavirin","hebert m.f.","guglielmo b.j."],"keywords":["*aerosol","*ribavirin","*ribavirin/ad [drug administration]","*ribavirin/ae [adverse drug reaction]","*ribavirin/cm [drug comparison]","*ribavirin/pd [pharmacology]","*ribavirin/pe [pharmacoeconomics]","*ribavirin/po [oral drug administration]","pharmacokinetics","arterial oxygen tension","article","artificial ventilation","atmosphere","clinical article","clinical trial","crystallization","disease severity","drug cost","drug efficacy","drug therapy","dyspnea/si [side effect]","endotracheal tube","environmental exposure","health care personnel","hospital","hospital admission","hospitalization","human","infant","lung function test","morbidity","mortality","placebo","priority journal","respiratory syncytial virus infection","safety","teratogenesis","treatment duration","ventilated patient","wheezing/si [side effect]"],"authorIDs":[],"dataSources":["9LqPNaySNpNxYBFzj"]}